SDC-1802 / Sareum - LARVOL DELTA

European Patent Granted for Sareum’s SDC-1802, a Novel Small Molecule TYK2/JAK1 Inhibitor, for the Treatment of T-cell Acute Lymphoblastic Leukaemia (PharmiWeb) - "Sareum Holdings...announces that...the European Patent Office has now issued a formal notification of grant for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 inhibitor programme. The patent will come into effect on 4 May 2022. The patent (EPO Patent no. EP3528806) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat T-cell acute lymphoblastic leukaemia (T-ALL – a cancer of a particular type of white blood cell called a T lymphocyte) and other cancers that are dependent on TYK2 kinase for survival."

Patent • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia

"European #Patent granted for #Sareums #SDC1802 $SAR https://t.co/hY94LcPhr6" (@1stOncology)

"Didn't Pfizer drop their #Tyk2 inhibitor #brepocitinib, any mention of @Sareum and their patented, wholly owned Tyk2/Jak1 inhibitors #SDC801 & #SDC1802" (@movinghousedjs)

TYK2

Sareum to Participate in the Edison Group’s Global Healthcare “Open House” Virtual Conference (25-27 January 2022) (PharmiWeb) - "Sareum Holdings...announces that the Company will be participating in Edison Group’s Global Healthcare 'Open House' Virtual Conference, taking place on 25-27 January 2022....At the event, Sareum’s Chief Executive Officer, Dr Tim Mitchell, will take part in a virtual interview to discuss the Company’s progress and strategy in 2022 with its lead TYK2/JAK1 inhibitor assets SDC-1801 and SDC-1802, as well as opportunities under consideration by licensee Sierra Oncology to advance Chk1 inhibitor SRA737."

Clinical • Oncology

"#SareumHoldingsPlc reported Intention to Grant Notice - EU #Patent for #SDC1802 $SAR https://t.co/yuTAQo3azp" (@1stOncology)

"#SareumHoldingsPlc reported that US #Patent Granted for #SDC1802 #TYK2 #JAK1 #Inhibitor $SAR https://t.co/TJZTGTXsbT" (@1stOncology)

JAK1 • TYK2

US Patent Granted for Sareum’s SDC-1802 TYK2/JAK1 Inhibitor (PharmiWeb) - "Sareum Holdings...announces that, further to its announcement of 30 July 2021, the United States Patent and Trademark Office has now formally approved its patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the 'SDC-1802 Programme'). The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase."

Patent • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Kidney Cancer • Melanoma • Oncology • Pancreatic Cancer • Solid Tumor • Urothelial Cancer

US Patent Notice of Allowance for Sareum’s SDC-1802 (Sareum Press Release) - "Sareum Holdings plc...announces that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme...The patent (US Patent Application no. 16/343,639) will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development....The Company expects that the patent will be granted within three months, subject to certain formalities being completed."

Patent • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Malignancies • Melanoma • Non-Hodgkin’s Lymphoma • Oncology • Pancreatic Cancer • Renal Cell Carcinoma

"@GileadSciences some Tyk2 @Sareumplc SDC-1801 & SDC-1802 Covid similar to Lupus & sepsis #CytokineStorm US Dept of Defence/SRI Lupus paper. https://t.co/4oFoAFLxaQ Chinese military saw actual muscle regrowth https://t.co/cAhlevzgMu Tyk2 in sepsis https://t.co/WXvXCVZhTu" (@sra737PRTeam)

Cytokine storm • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Septic Shock • TYK2

"Tyk2. Top of the 5 to treat #LongCovid #covid19 #covid #coronavirus 2nd on the list, IFNAR2. Inhibited by JAK1. @Sareumplc SDC-1801 & SDC-1802 inhibit both. Tyk2 and JAK1 inhibition You seeing this @GileadSciences @MSDintheUK @GSK @Novartis @TakedaOncology @bmsnews" (@sra737PRTeam)

Infectious Disease • Novel Coronavirus Disease • Oncology

Sareum : Final Results (Market Screener) - "SDC-1801 has demonstrated excellent tolerability in initial toxicology studies in rodents. A formulation that is predicted to deliver a therapeutic dose level has also been identified. If progress is successful, the application to commence first human trials is expected to be made during Q1 2021....SDC-1802: Formulation work for oral dosing of SDC-1802 is complete and toxicology studies and further manufacturing work are planned over the coming months."

New trial • Preclinical • Immunology • Inflammatory Bowel Disease • Lupus • Psoriasis

US Patent Allowance for Sareum’s SDC-1802 TYK2/JAK1 Inhibitor (Sareum Press Release) - “Sareum Holdings plc…is pleased to announce that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the ‘SDC-1802 Programme’). This programme is in preclinical development and targets cancer and cancer immunotherapy…the Company expects that the patent will be granted within three months.”

Patent • Immunology • Oncology